{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:17:05Z","timestamp":1791335825549,"version":"4.3.1"},"reference-count":24,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Tom &amp; Catherine Culley Charitable Trust to Banner MD Anderson Cancer Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: The mesenchymal\u2013epithelial transition (MET) exon 14 skipping mutation (METex14) is a rare genetic alteration occurring in non-small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) are the approved treatment for first-line therapy in a metastatic setting. However, the unusual presentation of gastrointestinal metastasis and leptomeningeal carcinomatosis (LMD) poses significant treatment challenges. Case Presentation: Here we report a case of a 72-year-old male with metastatic METex14-positive NSCLC, presenting with brain and duodenal metastases. Conclusions: The patient responded exceptionally well to first-line chemoimmunotherapy, achieving clinically complete remission for 2 years. He subsequently developed cerebellar metastasis and leptomeningeal disease (LMD) but demonstrated a remarkable response to tepotinib and continued to enjoy radiographic complete remission over 2.5 years at the time of this report.<\/jats:p>","DOI":"10.3390\/reports8020096","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:08:06Z","timestamp":1750219686000},"page":"96","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Leptomeningeal Disease with Tepotinib in a Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Presenting with Extensive Metastasis Involving Duodenum"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8835-9168","authenticated-orcid":false,"given":"Jacquelyn","family":"Shugarts","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Amado","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9908-3251","authenticated-orcid":false,"given":"Taylor","family":"Praska","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Camou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9018-287X","authenticated-orcid":false,"given":"Jiaxin","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1200\/PO.20.00516","article-title":"MET Exon 14 Skipping Mutations in Non\u2013Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations","volume":"5","author":"Socinski","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non\u2013Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non\u2013Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib Treatment in Patients with MET Exon 14\u2013Skipping Non\u2013Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1556-0864(15)30037-X","article-title":"Primary Lung Cancer Presenting with Gastrointestinal Tract Involvement: Clinicopathologic and Immunohistochemical Features in a Series of 18 Consecutive Cases","volume":"2","author":"Rossi","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/PO.20.00098","article-title":"CNS Metastases in Patients with MET Exon 14\u2013Altered Lung Cancers and Outcomes with Crizotinib","volume":"4","author":"Offin","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Neves, A., Mendon\u00e7a, I., da Cunha Marques, J.A., Costa, J., Almeida, J.S., Marques, J.A.D.C., and Almeida, J.S. (Cureus, 2023). Gastric Metastasis from Lung Adenocarcinoma: An Uncommon Presentation, Cureus, Epub ahead of print.","DOI":"10.7759\/cureus.34587"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s12325-024-02799-9","article-title":"Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review","volume":"41","author":"Khasraw","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal Metastasis from Non\u2013Small Cell Lung Cancer and Current Landscape of Treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pierret, T., Giaj-Levra, N., Toffart, A.-C., Alongi, F., Moro-Sibilot, D., and Gobbini, E. (2022). Immunotherapy in NSCLC Patients with Brain and Leptomeningeal Metastases. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.787080"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e28249","DOI":"10.1097\/MD.0000000000028249","article-title":"Gastric and colonic metastasis from NSCLC: A very unusual case report","volume":"101","author":"Catalano","year":"2022","journal-title":"Medicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/1759-7714.13815","article-title":"Non-small cell lung cancer with gastric metastasis and repeated gastrointestinal bleeding: A rare case report and literature review","volume":"12","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in Non\u2013Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/1759-7714.13871","article-title":"Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation","volume":"12","author":"Takamori","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.21037\/tcr-22-782","article-title":"Clinical and pathological characteristics of 11 NSCLC patients with c-MET exon 14 skipping","volume":"11","author":"Chen","year":"2022","journal-title":"Transl. Cancer Res. TCR"},{"key":"ref_16","first-page":"100145","article-title":"Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient with MET Exon 14 Skipping Mutation\u2013Positive Lung Adenocarcinoma: Case Report","volume":"2","author":"Ninomaru","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"a005785","DOI":"10.1101\/mcs.a005785","article-title":"Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: A research report","volume":"6","author":"Roth","year":"2020","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in Patients with Epidermal Growth Factor Receptor Mutation\u2013Positive Non\u2013Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2021.11.020","article-title":"Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases","volume":"163","author":"Clark","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11523-022-00912-y","article-title":"Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors","volume":"17","author":"Nishio","year":"2022","journal-title":"Targ. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jtho.2023.09.1444","article-title":"Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to \u201cFalse\u201d Decreases in Renal Function","volume":"19","author":"Chen","year":"2024","journal-title":"J. Thorac. Oncol."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/96\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:53:57Z","timestamp":1760032437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/96"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["reports8020096"],"URL":"https:\/\/doi.org\/10.3390\/reports8020096","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}